Easterly Investment Partners LLC Buys 25,211 Shares of Johnson & Johnson (NYSE:JNJ)

Easterly Investment Partners LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 27.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 117,025 shares of the company’s stock after acquiring an additional 25,211 shares during the period. Johnson & Johnson accounts for approximately 1.6% of Easterly Investment Partners LLC’s portfolio, making the stock its 11th largest holding. Easterly Investment Partners LLC’s holdings in Johnson & Johnson were worth $19,407,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. MRP Capital Investments LLC grew its holdings in Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company’s stock worth $237,000 after purchasing an additional 65 shares during the period. Syverson Strege & Co grew its stake in Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company’s stock valued at $202,000 after acquiring an additional 65 shares in the last quarter. MBA Advisors LLC grew its stake in shares of Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after buying an additional 68 shares in the last quarter. Sovereign Financial Group Inc. boosted its stake in shares of Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after purchasing an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc boosted its position in Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock valued at $767,000 after buying an additional 69 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. Guggenheim upped their price objective on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a “neutral” rating in a report on Thursday. Raymond James Financial lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Wall Street Zen upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 21st. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Eleven research analysts have rated the stock with a hold rating, nine have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $174.11.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $163.04 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The firm’s 50 day moving average price is $154.10 and its 200-day moving average price is $154.84. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a market cap of $392.28 billion, a P/E ratio of 17.44, a P/E/G ratio of 2.21 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the firm posted $2.82 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.19%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.